Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, Zantac
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
GSK to Settle 80,000 Zantac Cases for Up to $2.2 Billion
GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The cases represent about 93% of those against the company involving Zantac,
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.
Zantac Maker GSK Says It Reaches $2.3 Bn Settlement In US
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
ENDPOINTS NEWS
15h
Two GSK trials with long-acting drug in chronic rhinosinusitis hit primary endpoints
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...
1d
GSK Says Potential Blockbuster Helps Treat Common Nasal Disease
GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...
FierceBiotech
22h
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
BioPharma Dive
14h
GSK says antibody drug succeeds in testing for chronic nasal condition
The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.
Hosted on MSN
4d
GSK settles vast majority of Zantac claims for $2.2 billion
GSK
has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its ...
18h
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...
Becker's Hospital Review
9h
New drug can treat common nasal disease: GSK
GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.
pharmaphorum
21h
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
GlaxoSmithKline
Zantac
Inflation
Depemokimab
Ranitidine
Feedback